The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.
Hutchmed Ltd. plans to file a second NDA in China for sovleplenib, a novel spleen tyrosine kinase inhibitor, based on positive phase II/III findings in warm antibody autoimmune hemolytic anemia.
Takeda Pharmaceuticals Co. Ltd.’s oral tyrosine kinase 2 inhibitor, zasocitinib (TAK-279), met the co-primary endpoints and all ranked secondary endpoints in two pivotal phase III studies in patients with moderate to severe plaque psoriasis.
There are two significant messages for companies developing and profiting from obesity drugs in a meta-analysis of clinical trials examining the extent of weight regain after treatment stops. First, people taking obesity medication regain weight four times faster on average than those who lose weight through behavioral diet and exercise programs; and second, poor tolerability leads to poor adherence.
Having nailed down alignment with the U.S. FDA in December on a phase III trial that will start in the middle of this year, Immuneering Corp. updated the overall survival and safety data from an ongoing phase IIa trial testing atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients (n=34), with more than 13 months median follow-up time.
News of Eli Lilly and Co. purchasing Ventyx Biosciences Inc. for $14 per share arrived after market close Jan. 7, following unconfirmed rumors of the buyout that drove shares up by more than 52% at one point.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Alkermes, Ark, Bioarctic, Biogen, Biosplice, Cellenkos, Eisai, GSK, Johnson & Johnson, Milestone, Oculis, Zai Lab.
Biopharma happenings, including deals and partnerships, and other news in brief: Astrazeneca, Boehringer Ingelheim, Bostongene, Cartography, Convergent, Day One, Galapagos, Gasherbrum, Genentech, Gilead, Factor, Immuneonco, Instil, Lineage Cell, Mersana, Northstar Medical Radioisotopes, Onconano, Pfizer, Variant.
RSS
